Covered recipient · General Payments record
NATALIE DANIELLE GORDON
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2023–2025
$618.48
- Reported across 12 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $393.75 | 10 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $135.70 | 2 |
| Lilly USA, LLC | $107.48 | 1 |
| Verity Pharmaceuticals Inc. | $30.96 | 1 |
| PFIZER INC. | $26.84 | 1 |
| ABIOMED | $22.76 | 1 |
| Almatica Pharma LLC | $22.25 | 1 |
| GlaxoSmithKline, LLC. | $18.76 | 1 |
| Corcept Therapeutics | $15.28 | 1 |
| Novo Nordisk AS | $13.72 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABIOMED | $22.76 | 09/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1175052533 | CMS |
| Almatica Pharma LLC | $22.25 | 06/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1209932072 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.90 | 02/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1206335267 | CMS |
| AstraZeneca Pharmaceuticals LP | $121.80 | 09/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1206334166 | CMS |
| Corcept Therapeutics | $15.28 | 08/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1214158098 | CMS |
| GlaxoSmithKline, LLC. | $18.76 | 11/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190691544 | CMS |
| Lilly USA, LLC | $107.48 | 11/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186768324 | CMS |
| Novo Nordisk Inc | $13.72 | 06/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189011557 | CMS |
| PFIZER INC. | $26.84 | 02/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1229088991 | CMS |
| Verity Pharmaceuticals Inc. | $30.96 | 10/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234200584 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.